116 related articles for article (PubMed ID: 7004664)
1. Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
Faraj BA; Lawson DH; Nixon DW; Murray DR; Camp VM; Ali FM; Black M; Stacciarini W; Tarcan Y
Clin Chem; 1981 Jan; 27(1):108-12. PubMed ID: 7004664
[TBL] [Abstract][Full Text] [Related]
2. [Fluorimetric assay of 3-o-methyldopamine and 4-0-methyldopamine in rat urine and o-methylation of dopamine].
Bidard JN; Cronenberger L
C R Acad Hebd Seances Acad Sci D; 1977 Jan; 284(5):389-92. PubMed ID: 404066
[TBL] [Abstract][Full Text] [Related]
3. [Identification of 4-O-methyldopamine in rat tissues by reverded-phase liquid chromatography (author's transl)].
Bidard JN; Cronenberger L
J Chromatogr; 1979 Oct; 164(2):139-54. PubMed ID: 541405
[TBL] [Abstract][Full Text] [Related]
4. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
[TBL] [Abstract][Full Text] [Related]
5. Heart failure, aging, and renal synthesis of dopamine.
Ferreira A; Bettencourt P; Pestana M; Correia F; Serrão P; Martins L; Cerqueira-Gomes M; Soares-Da-Silva P
Am J Kidney Dis; 2001 Sep; 38(3):502-9. PubMed ID: 11532681
[TBL] [Abstract][Full Text] [Related]
6. [Importance of urinary 3-O methyldopamine in the metabolism of adrenergic tumors].
Dalmaz Y; Peyrin L
Ann Endocrinol (Paris); 1975; 36(4):189-204. PubMed ID: 1203011
[TBL] [Abstract][Full Text] [Related]
7. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD; Ruthven CR; Goodwin BL; Sandler M
J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
Tuomainen P; Männistö PT
Eur J Clin Chem Clin Biochem; 1997 Mar; 35(3):229-35. PubMed ID: 9127745
[TBL] [Abstract][Full Text] [Related]
9. The measurement of 3-o-methyldopamine in urine and plasma by a rapid and specific radioimmunoassay.
Faraj BA; Camp VM; Pruitt AW; Isaacs JW; Ali FM
J Nucl Med; 1977 Oct; 18(10):1027-33. PubMed ID: 903469
[TBL] [Abstract][Full Text] [Related]
10. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
11. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
12. 3-O-methyl-alpha-methyldopamine, a urinary metabolite of p-methoxyamphetamine in dog and monkey.
Hubbard JW; Bailey K; Midha KK; Cooper JK
Drug Metab Dispos; 1981; 9(3):250-4. PubMed ID: 6113935
[TBL] [Abstract][Full Text] [Related]
13. Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
Dalmaz Y; Peyrin L
J Chromatogr; 1976 Jan; 116(2):379-941. PubMed ID: 1415
[TBL] [Abstract][Full Text] [Related]
14. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
15. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.
Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P
Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191
[TBL] [Abstract][Full Text] [Related]
16. Identification of 3-O-methyl-alpha-methyldopamine as a urinary metabolite of 3,4-methylenedioxyamphetamine in dog and monkey.
Midha KK; Cooper JK; By A; Ethier JC
Drug Metab Dispos; 1977; 5(2):143-8. PubMed ID: 15806
[TBL] [Abstract][Full Text] [Related]
17. A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine.
Brown MJ; Dollery CT
Br J Clin Pharmacol; 1981 Jan; 11(1):79-83. PubMed ID: 6783056
[TBL] [Abstract][Full Text] [Related]
18. Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.
Soares-da-Silva P; Pestana M; Vieira-Coelho MA; Fernandes MH; Albino-Teixeira A
Br J Pharmacol; 1995 Apr; 114(7):1403-13. PubMed ID: 7541690
[TBL] [Abstract][Full Text] [Related]
19. Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetics in dogs.
Pocchiari F; Pataccini R; Castelnovo P; Longo A; Paro M; Casagrande C
Arzneimittelforschung; 1986 Feb; 36(2A):341-4. PubMed ID: 3707646
[TBL] [Abstract][Full Text] [Related]
20. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
